Zevra Therapeutics, Inc. (ZVRA) income statement
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$8.76−0.31 (-3.42%)
Close on Nov 20, 2026Market cap $520.20MP/E 9.4Yield –
Zevra Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 95.5%
- Operating margin
- 60.5%
- Net margin
- 42.8%
- Return on equity, FY2025
- 85.7%
Financial strength
- Current ratio
- 5.17
- Debt to equity
- 0.00
- Debt to assets
- 0.0%
- Cash to current liabilities
- 298.8%
Valuation
- P/E ratio
- 9.4
- Price to sales
- 3.82
- Price to book
- 2.39
- Dividend yield
- –
See a number that looks wrong?